Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TEBENTAFUSP-TEBN Cause Product dose omission issue? 37 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 37 reports of Product dose omission issue have been filed in association with TEBENTAFUSP-TEBN. This represents 10.6% of all adverse event reports for TEBENTAFUSP-TEBN.

37
Reports of Product dose omission issue with TEBENTAFUSP-TEBN
10.6%
of all TEBENTAFUSP-TEBN reports
0
Deaths
11
Hospitalizations

How Dangerous Is Product dose omission issue From TEBENTAFUSP-TEBN?

Of the 37 reports, 11 (29.7%) required hospitalization, and 2 (5.4%) were considered life-threatening.

Is Product dose omission issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TEBENTAFUSP-TEBN. However, 37 reports have been filed with the FAERS database.

What Other Side Effects Does TEBENTAFUSP-TEBN Cause?

Pyrexia (63) Cytokine release syndrome (59) Hypotension (47) Rash (43) Disease progression (42) Chills (38) Malignant neoplasm progression (32) Nausea (29) Vomiting (22) Pruritus (21)

What Other Drugs Cause Product dose omission issue?

DUPILUMAB (18,189) USTEKINUMAB (9,405) GUSELKUMAB (9,267) LENALIDOMIDE (8,145) MEPOLIZUMAB (5,873) TOFACITINIB (5,646) VOXELOTOR (5,122) BELIMUMAB (4,671) SECUKINUMAB (4,572) APREMILAST (4,460)

Which TEBENTAFUSP-TEBN Alternatives Have Lower Product dose omission issue Risk?

TEBENTAFUSP-TEBN vs TECFIDERA TEBENTAFUSP-TEBN vs TECHNETIUM TC-99M TEBENTAFUSP-TEBN vs TECHNETIUM TC-99M MEDRONATE TEBENTAFUSP-TEBN vs TECHNETIUM TC-99M OXIDRONATE TEBENTAFUSP-TEBN vs TECHNETIUM TC-99M PERTECHNETATE

Related Pages

TEBENTAFUSP-TEBN Full Profile All Product dose omission issue Reports All Drugs Causing Product dose omission issue TEBENTAFUSP-TEBN Demographics